Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT

View CSAF Summary Successful exploitation of these vulnerabilities could allow an attacker to obtain sensitive health-related information and prevent legitimate users from establishing a connection with the device. The following versions of Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT are affected: Blood Glucose Monitoring System (Model No. APG-01 BT) 0x0110_v1.1.0 (CVE-2026-50034, CVE-2026-52866) CVSS Vendor Equipment Vulnerabilities v3 6.5 Apollo Pharmacy Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Cleartext Transmission of Sensitive Information, Missing Authorization Background Critical Infrastructure Sectors: Healthcare and Public Health Countries/Areas Deployed: India Company Headquarters Location: India Vulnerabilities Expand All + CVE-2026-50034 An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values. View CVE Details Affected Products Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Vendor: Apollo Pharmacy Product Version: Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT): 0x0110_v1.1.0 Product Status: known_affected Remediations Mitigation Apollo Pharmacy did not respond to CISA's requests to coordinate. Users are encouraged to reach out to Apollo Pharmacy directly for more information:https://www.apollopharmacy.in/contact-us. https://www.apollopharmacy.in/contact-us Mitigation CISA recommends users follow the guidance in the Understanding Bluetooth Technology blog https://www.cisa.gov/news-events/news/understanding-bluetooth-technology. https://www.cisa.gov/news-events/news/understanding-bluetooth-technology Relevant CWE: CWE-319 Cleartext Transmission of Sensitive Information Metrics CVSS Version Base Score Base Severity Vector String 3.1 6.5 MEDIUM CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N 4.0 7.1 HIGH CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N CVE-2026-52866 An attacker within BLE communication range can monopolize the device's only available BLE connection slot, preventing legitimate users or applications from establishing a connection. View CVE Details Affected Products Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Vendor: Apollo Pharmacy Product Version: Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT): 0x0110_v1.1.0 Product Status: known_affected Remediations Mitigation Apollo Pharmacy did not respond to CISA's requests to coordinate. Users are encouraged to reach out to Apollo Pharmacy directly for more information:https://www.apollopharmacy.in/contact-us. https://www.apollopharmacy.in/contact-us Mitigation CISA recommends users follow the guidance in the Understanding Bluetooth Technology blog https://www.cisa.gov/news-events/news/understanding-bluetooth-technology. https://www.cisa.gov/news-events/news/understanding-bluetooth-technology Relevant CWE: CWE-862 Missing Authorization Metrics CVSS Version Base Score Base Severity Vector String 3.1 6.5 MEDIUM CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H 4.0 7.1 HIGH CVSS:4.0/AV:A/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N Acknowledgments Rishitha Pucchakayala and Centre for Development of Advanced Computing (Hyderabad) reported these vulnerabilities to CISA Legal Notice and Terms of Use This product is provided subject to this Notification (https://www.cisa.gov/notification) and this Privacy & Use policy (https://www.cisa.gov/privacy-policy). Recommended Practices CISA recommends users take defensive measures to minimize the risk of exploitation of these vulnerabilities. Minimize network exposure for all control system devices and/or systems, ensuring they are not accessible from the internet. Locate control system networks and remote devices behind firewalls and isolating them from business networks. When remote access is required, use more secure methods, such as Virtual Private Networks (VPNs), recognizing VPNs may have vulnerabil